Genome-Wide DNA Methylation Markers Associated With Metabolic Liver Cancer

Area of Science:

• Epigenetics and Cancer Research
• Metabolic Disease Mechanisms
• Hepatocellular Carcinoma Etiology

Background:

• Metabolic liver disease is a rapidly growing cause of hepatocellular carcinoma (HCC).
• The molecular mechanisms linking metabolic dysfunction to HCC development remain largely unknown.
• Aberrant DNA methylation is investigated as a potential driver in metabolic HCC.

Purpose of the Study:

• To investigate the role of DNA methylation in the development of metabolic HCC.
• To identify blood-based DNA methylation markers for differentiating metabolic HCC from benign metabolic liver disease.

Main Methods:

• A multicenter, international case-control study.
• Genome-wide DNA methylation profiling of peripheral blood leukocytes using the 850k EPIC array.
• Differential methylation analysis adjusted for cell type proportions and clinical factors.

Main Results:

• Identified 55 differentially methylated CpGs (33 hypermethylated, 22 hypomethylated) in metabolic HCC cases versus controls.
• A 55-CpG panel achieved an AUC of 0.79 for differentiating cases from controls.
• The 55-CpG panel combined with clinical factors (age, sex, race, diabetes) yielded an AUC of 0.78.

Conclusions:

• A panel of 55 blood DNA methylation markers can distinguish metabolic HCC from benign metabolic liver disease.
• This methylation panel demonstrates potential as a non-invasive biomarker for metabolic HCC detection.
• Combining methylation markers with clinical data may improve diagnostic accuracy for metabolic HCC.